On ECHEMI
Home > Drugs > Shaanxi Kaiyuan Pharmaceutical Co., Ltd.
Shaanxi Kaiyuan Pharmaceutical Co., Ltd.
  • Founded in:

    1996-06-07
  • Country:

    China China
  • Address:

    No. 68, West Avenue, High-tech Zone, Xi'an, Shaanxi Province
  • Tax NO.:

    91610000623107963J
  • Registered Funds:

    25 million yuan
  • Website:

  • Email:

Related Drugs
Rupishu Tablets
Name Description Content CAS NO. Registered Holders
Rupishu Tablets

0
Cerebroprotein Hydrolysate Injection
This product is a polypeptide preparation made by enzymatic hydrolysis of pig brain protein. The solution used for injection or drip does not contain protein, fat and other antigenic substances. Each milliliter of this product contains 215.2 mg of pig brain protein hydrolyzate.
Name Description Content CAS NO. Registered Holders
Porcine brain protein hydrolysate

It accelerates the development of the chicken brain, is beneficial to the protein synthesis of nerve cells and their respiratory chain, and stimulates the production of related hormones at the same time; it can effectively protect the central nervous system from toxic substances; it improves the rat's ability to resist hypoxia; the brain maturation of rats a few days after medication is significantly accelerated, and the recognition ability of adult rats in the maze test is enhanced; the glucose turnover speed in the blood-brain barrier of rats using this product group is significantly accelerated. Toxicological studies have shown that human use of this drug will not cause the risk of chronic toxicity, reproductive toxicity, mutagenicity and carcinogenicity.

More

It accelerates the development of the chicken brain, is beneficial to the protein synthesis of nerve cells and their respiratory chain, and stimulates the production of related hormones at the same time; it can effectively protect the central nervous system from toxic substances; it improves the rat's ability to resist hypoxia; the brain maturation of rats a few days after medication is significantly accelerated, and the recognition ability of adult rats in the maze test is enhanced; the glucose turnover speed in the blood-brain barrier of rats using this product group is significantly accelerated. Toxicological studies have shown that human use of this drug will not cause the risk of chronic toxicity, reproductive toxicity, mutagenicity and carcinogenicity.

215.2mg 0
Aceclofenac Enteric-coated Capsules
The main ingredient of this product is aceclofenac
Name Description Content CAS NO. Registered Holders
Aceclofenac

This product is a non-steroidal anti-inflammatory drug with anti-inflammatory and analgesic effects. Its mechanism of action may be mainly through inhibiting cyclooxygenase activity, thereby reducing prostaglandin synthesis.

More

This product is a non-steroidal anti-inflammatory drug with anti-inflammatory and analgesic effects. Its mechanism of action may be mainly through inhibiting cyclooxygenase activity, thereby reducing prostaglandin synthesis.

89796-99-6 14
Lige Granules
Radish seeds, kudzu root, and hawthorn.
Name Description Content CAS NO. Registered Holders
Radish seed

0
Puerariae Lobatae Radix

0
Hawthorn

0
Nicardipine Hydrochloride Injection
Nicardipine hydrochloride. Chemical name: 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid-3-[(N-benzyl-N-methylamino)]-ethyl ester-5-methyl ester hydrochloride. Its structural formula is: Molecular formula: C28H20N3O6, HCl Molecular weight: 515.99
Name Description Content CAS NO. Registered Holders
Nicardipine hydrochloride

This product inhibits the transmembrane calcium ion influx of myocardial and vascular smooth muscle without changing the blood calcium concentration. Its effect on vascular smooth muscle is better than that on myocardial, so its vascular selectivity is relatively strong. In animal experiments, this product selectively dilates coronary vascular smooth muscle. The blood drug concentration when this effect occurs does not produce negative inotropic effect (myocardial), and has little effect on heart rhythm and cardiac contractility. In the human body, this product reduces peripheral vascular resistance. This effect is greater in patients with hypertension than in those with normal blood pressure. When blood pressure is lowered, there will be a reflex increase in heart rate. This product increases cardiac ejection fraction and cardiac output, while the left ventricular end-diastolic pressure does not change much. It can reduce myocardial oxygen consumption and total peripheral resistance, and can also increase coronary collateral circulation and increase coronary blood flow. This product is a dihydropyridine calcium antagonist that can block the influx of calcium ions into vascular smooth muscle cells, thereby dilating blood vessels and lowering blood pressure.

More

This product inhibits the transmembrane calcium ion influx of myocardial and vascular smooth muscle without changing the blood calcium concentration. Its effect on vascular smooth muscle is better than that on myocardial, so its vascular selectivity is relatively strong. In animal experiments, this product selectively dilates coronary vascular smooth muscle. The blood drug concentration when this effect occurs does not produce negative inotropic effect (myocardial), and has little effect on heart rhythm and cardiac contractility. In the human body, this product reduces peripheral vascular resistance. This effect is greater in patients with hypertension than in those with normal blood pressure. When blood pressure is lowered, there will be a reflex increase in heart rate. This product increases cardiac ejection fraction and cardiac output, while the left ventricular end-diastolic pressure does not change much. It can reduce myocardial oxygen consumption and total peripheral resistance, and can also increase coronary collateral circulation and increase coronary blood flow. This product is a dihydropyridine calcium antagonist that can block the influx of calcium ions into vascular smooth muscle cells, thereby dilating blood vessels and lowering blood pressure.

54527-84-3 33
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.